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Positron emission tomography (PET) with the drug radiolabelled allows a direct measurement
of brain or other organ kinetics, information which can be essential in drug development. Usually,
however, a PET-tracer is administered intravenously (i.v.), whereas the therapeutic drug is mostly
given orally or by a different route to the PET-tracer. In such cases, a recalculation is needed
to make the PET data representative for the alternative administration route. To investigate the
blood–brain barrier penetration of a drug (zolmitriptan) using dynamic PET and by PK model-
ling quantify the brain concentration of the drug after the nasal administration of a therapeutic
dose. [11C]Zolmitriptan at tracer dose was administered as a short i.v. infusion and the brain
tissue and venous blood kinetics of [11C]zolmitriptan was measured by PET in 7 healthy vol-
unteers. One PET study was performed before and one 30min after the administration of 5mg
zolmitriptan as nasal spray. At each of the instances, the brain radioactivity concentration after
subtraction of the vascular component was determined up to 90min after administration and com-
pared to venous plasma radioactivity concentration after correction for radiolabelled metabolites.
Convolution methods were used to describe the relationship between arterial and venous tracer
concentrations, respectively between brain and arterial tracer concentration. Finally, the impulse
response functions derived from the PET studies were applied on plasma PK data to estimate the
brain zolmitriptan concentration after a nasal administration of a therapeutic dose. The studies
shows that the PET data on brain kinetics could well be described as the convolution of venous
tracer kinetics with an impulse response including terms for arterial-to-venous plasma and arte-
rial-to-brain impulse responses. Application of the PET derived impulse responses on the plasma
PK from nasal administration demonstrated that brain PK of zolmitriptan increased with time,
achieving about 0.5mg/ml at 30min and close to a maximum of 1.5mg/ml after 2 hr. A significant
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brain concentration was observed already after 5min. The data support the notation of a rapid
brain availability of zolmitriptan after nasal administration.
KEY WORDS: positron emission tomography; zolmitriptan; modelling; convolution; brain;
pharmacokinetics.
INTRODUCTION
Positron emission tomography (PET) is becoming more widely used
and proven as an important tool in drug development (1–4). One reason
for this is the development of new labelling methods that allow a multi-
tude of candidate or existing drugs to be labelled with positron emitting
radionuclides. In particular, a new option to use [11C]CO as the synthon
has enabled a range of chemical entities to be labelled and their in vivo
kinetics probed (5).
PET studies for drug development has until now predominantly expl-
ored a drug’s effect on a target system using a tracer specific for this target
and evaluation of the reduction of the tracer binding, interpreted in terms
of the drugs inhibition or occupancy of the target system (6). Although cru-
cial in the early drug development (7,8) standard PK studies do not reveal
organ distribution, and only sometimes can reasonable assessments be made
in this respect, by combining human PK data with information from ani-
mal studies. This is a case where PET gives unique possibilities. Utilising a
drug candidate labelled with a positron emitting radionuclide, PET allows
direct recording of the labelled drug’s distribution within the body (9–13). A
high temporal and spatial resolution, plus tomographic imaging with excel-
lent quantitative accuracy, are features which give PET an important role in
drug distribution studies (14). The major technical drawbacks include lim-
ited follow up times, reduced to a few half-lives of the radionuclide. In stud-
ies with 11C, the half-life of 20min restricts the follow up times to about
1.5 hr. Another important aspect is that PET does not allow a discrimi-
nation between labelled entities and hence radioactive native compound is
interpreted together with possible radiolabelled metabolites.
A PET study allows accurate determinations of radioactivity concentra-
tion, and with the limitations given above, this can be recalculated into drug
concentrations when tracer and cold compound is co-administered. This is
based on the fact that the relation between radiolabelled and non-labelled
drug is maintained since they are chemically identical and hence have iden-
tical distribution and elimination. In this way the organ kinetics of a drug
can be determined in a PET study in absolute terms.
However, PET studies are preferably performed with the tracer given
as intravenously (i.v.) injection because through this route of administra-
tion the radioactivity is rapidly distributed in the body. With oral or other
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administration routes the amount of radioactivity given must be reduced
for radiation safety concerns. A very localized radioactivity such as in a
small volume swallowed, could potentially give rise to a locally high radi-
ation dose to an aspect of the gastro-intestinal tract. Oral administrations
are therefore performed with about a 10–20 fold reduction in given radio-
activity (1,15) and are therefore associated with an impaired image qual-
ity and impaired precision in the measurements. In order to overcome
this dilemma, a possibility is to perform a PET study with i.v. admin-
istration of the tracer and observation of organ kinetics associated with
this. Together with tracer kinetics in plasma a PK-model is generated to
describe the rate of tracer exchange between plasma and organ (9). There-
after this model is used for the calculation of organ “cold drug” kinetics,
using PK after oral administration as input.
Zolmitriptan is widely used as an effective anti-migraine treatment. A
new nasal spray formulation is associated with a more rapid appearance in
plasma (from 2min post dose) and a more rapid relief from the migraine
pain (from 10min post dose) (16–18). The mechanism of action is believed
to be agonistic effects on 5HT1B/1D-receptors and it has been suggested
that this action by zolmitriptan is exerted both at the vascular level and in
the brain parenchyma. Since no data were available on the entry of zolmi-
triptan over the blood–brain barrier (BBB), a PET study was initiated for
the determination of zolmitriptan kinetics in brain.
The purpose of the present communication is to illustrate this sug-
gested concept of generating organ distribution data, utilising data from a
study of the distribution of 11C-labelled zolmitriptan into brain as assessed
by PET after i.v. administration of the tracer, and combining it with cold
zolmitriptan administered as a nasal spray. The clinical data are included
in a separate communication (19).
MATERIALS AND METHODS
Eight healthy volunteers, 5men and 3women were recruited for the
studies. Each volunteer underwent the same procedures, including one
PET study with 15O–CO for the determination of region blood vol-
ume in the brain and one 11C-zolmitriptan brain distribution study. This
was followed by a nasal spray administration of 5mg unlabelled zolmi-
triptan. Thirty minutes later a new 11C-zolmitriptan brain distribution
study was performed. An additional PET study with 15O-water and an
MRI study was inserted for anatomical localisation. The 11C-zolmitrip-
tan PET-investigations included a 5min i.v. infusion of about 600MBq
11C-zolmitriptan and dynamic imaging with 18 frames (5 frames of 60 s
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each, 5× 180, 2× 300, 6× 600 s) acquired during 90min. The studies were
made in three dimensional (3D) mode on a CTI HR+PET-camera with
64 tomographic images obtained simultaneously covering an axial field of
view of 15 cm. The spatial resolution was approximately 5mm using the
supplied 3D filtered backprojection algorithm.
During each of the 11C-zolmitriptan studies, 11 venous blood sam-
ples were taken for the determination of blood and plasma radioactiv-
ity concentration. Four additional blood samples were taken and used
for the determination of intact 11C-zolmitriptan and its prime metabolite
11C-183C91. Further plasma samples were taken after nasal administra-
tion of zolmitriptan for the determination of PK of zolmitriptan and its
prime metabolite 183C91.
Since blood sampling failed during the first 5min in one individual,
the data from that person was not used and only 7 studies are included in
this report.
The studies were performed with informed consent from the volun-
teers and with permissions from the Local Ethics Committee, Radiation
Ethics Committee and the Swedish Medical Products Agency.
Generation of Quantitative Data
The images were reconstructed with attenuation and scatter correction
(Fig. 1). In the 11C-zolmitriptan images regions of interest were outlined
to represent different grey matter regions. For each of the regions, time-
activity data were generated and recalculated as SUV values.
SUV = local radioactivity concentration (Bq/g)/(injected radioactivity
(kBq)/body weight(kg)).
The radioactivity concentration in each region was corrected for vas-
cular tracer contribution by subtracting the product of local blood volume
(obtained from the 15O–CO study) and whole blood radioactivity concen-
tration for each time point (also represented in SUV).
The brain time-activity curves were averaged for all grey matter
regions within each individual, after subtraction of vascular contribution
(Fig. 2).
Utilising HPLC-separation, the radioactivity in plasma samples were
analysed with respect to intact 11C-zolmitriptan and 11C-183C91. Since both
these are pharmacologically active and brain penetrating, the combined frac-
tion of total plasma radioactivity constituted by these two was determined
for the four different time points. For each individual a bi-exponential func-
tion, conditioned to be 100% at time zero, was fitted to these data. Then
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Fig. 1. PET images over a central part of the brain, obtained after administration of
11C-zolmitriptan. Upper three rows show sequential caudal to cranial transaxial slices.
Lower images show midline sagittal (left) and coronal (right) slices. The highest uptake is
noted in extracranial structures, and a low uptake is seen in brain tissue.
the plasma radioactivity was multiplied by the data from this bi-exponen-
tial, to obtain plasma values corrected for other metabolites than 183C91.
The plasma time-activity data were expressed in SUV (Fig. 2).
Deconvolution of Brain Time-Activity Data
With the assumption that the transfer of drug from capillaries to
brain parenchyma is linear with respect to concentration and time inde-
pendent, that is at each time point and for each concentration in plasma
the rate constants for transport of drug across the BBB are the same, a
so-called convolution method could be applied. This can be understood as
that the time course of plasma concentration in the capillaries is divided
into small portions, e.g. every second, and the fate of drug during each
of these time periods is handled separately. Hence, the exposure from one
such period will lead to a certain uptake in brain, followed by a washout
since no further exposure is given. This is what we define as the impulse
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Fig. 2. Time activity curves of brain tissue (PET1 and PET2) and venous plasma, expressed
in SUV. Higher curves show plasma and lower curves brain concentrations from the two
different studies, before (full lines, PET1 and plsm1) and after nasal administration of zolmi-
triptan (broken lines, triangles, PET2 and plsm2). The highest values are seen in plasma, with
peak SUV of 2.2 whereas brain concentration reaches a maximum of about 0.2. The data
from the two occasions are very similar. Averages of all individuals with plasma corrected for
metabolites and brain values corrected for vascular contribution.
response if we normalize for the plasma concentration of the period. The
overall resulting brain kinetics will be the summation of each small con-
tribution which in turn will be the impulse response multiplied by the
momentary plasma concentration.
The brain PET data is represented by the impulse response, convolv-
ing the full capillary plasma time-activity data (20,21):
B(t) = I(t) ⊗ A(t), (1)
where B(t) represents brain time-activity data, A(t) represents capillary
plasma time-activity data, I(t) represents impulse response from capillary
to brain and ⊗ denotes convolution.
Since venous blood samples were used for the determination of
plasma time-activity data, a correction must be made for the fact that
arterial and capillary time-activity data are different from venous time-
activity data (22). This correction was based on the assumption that the
passage of tracer from arterial plasma via the tissue to venous plasma
could be described as composed of two components: one component
representing plasma from which no extraction to tissue occurs and one
component where a certain fraction E is extracted. The extracted radioac-
tivity is then assumed to have a first order elimination kinetics from tissue
to plasma. With this assumption, an impulse response can be defined to
represent the relation between arterial plasma and venous plasma:
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V(t) = g(t) ⊗ A(t) (2)
g(t) = (1 − E) ∗ t for t < t
g(t) = k ∗ E ∗ exp(−a ∗ t) for t > t, (3)
where V(t) represents venous blood time-activity data, A(t) represents
arterial blood time-activity data, g(t) represents impulse response from
arterial to venous plasma, ⊗ denotes convolution, E= extraction during
passage from artery to vein in the hand, t represents transit time from
capillary to venoules, a represents an exponential for the washout from
hand tissue and, the constant k is set so that the integral of g(t) = 1.
We define now a new function g−1(t) such that:
B(t) = [g−1(t) ⊗ I(t)] ⊗ V(t). (4)
In order to solve the relationship between venous plasma time-activity
V(t) and brain time-activity B(t), a program was written in MATLAB which
iteratively fitted Eq. (4) to PET data. Hence I(t) was described as a tri-
exponential function with 6 free parameters to allow sufficient degrees of
freedom, and g−1(t) was described by three singular terms, hence 3 free
parameters (see below). These free parameters were iteratively optimized
so that the convolution according to Eq. (4) fitted the data of B(t).
Convolution of PK Data
With the assumption that PET-data could supply an impulse response,
describing the relation between brain time-activity data and venous plasma
time-activity data, and with the assumption that the relationship between
brain and plasma is time invariant and linear, brain PK data can be
obtained as a convolution of plasma PK-data with this impulse response.
Bc(t) = [g−1(t) ⊗ I(t)] ⊗ Vc(t), (5)
where now Bc(t) equals brain kinetics of cold zolmitriptan and Vc(t)
equals venous plasma PK of zolmitriptan, g−1(t) and I(t) are the impulse
responses obtained in the PET study.
There is always a risk that the transfer from plasma to brain is non-
linear with respect to plasma concentration, that is proportionally less or
more of drug enters the brain when plasma concentration of drug changes.
This can happen e.g. if active transport systems or efflux systems become
saturated as the drug concentration increases. Therefore the PET investiga-
tions with 11C-zolmitriptan were performed under two different conditions:
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at tracer alone doses and at a time when cold zolmitriptan had reached close
to its maximum in plasma. In the first instance the plasma concentration is
of the order of nM while in the second it is of the order of µM. A com-
parison of these two allows an assessment if brain penetration is dependent
upon the plasma concentration of cold compound. In the present case the
impulse response functions were similar at the two occasions and an average
of the two, to reduce statistical variations, was used.
RESULTS
Convolution Arterial to Venous Plasma
Using an arterial to venous convolution function g(t) as defined
above, and a simulated arterial function, a venous function was gener-
ated (Fig. 3). This venous function was then converted to the original
arterial function by convolution with an “inverse” function specified by a
3–5 value function with an initial positive value and negative followers.
The deconvolution of simulated venous curve to an arterial curve restored
the original with a difference in area less than 1%.
Convolution Function Plasma to Brain
Fitting of a plasma-to-brain impulse response, described solely by the
sum of three exponentials, to data utilising Eq. (1) resulted after reconvo-
lution in values which clearly did not fit well to the original data (Fig. 4).
Applied on the average data, the area under the curve difference was 10%.
The errors were especially pronounced in the early time period where the
peak was delayed as compared to the original data.
When an arterial-to-venous convolution function was included, the
curve generated fitted much better to the data. If the average of all brain
curves and the average of all plasma curves were generated for the whole
group, and the method suggested was applied on these averages, the area
under curve deviation was 2.2%. Applied in all individual studies, the area
under curve deviation was on the average 4.2% (SD 2.1 and range 2.0–9.3).
The convolution function obtained by only utilising a three-exponential
as impulse response had a rapidly reducing aspect initially followed
by almost constant values (Fig. 5). The convolution function includ-
ing arterial-to-venous convolution had one initial high value, followed by
two negative values and thereafter a close to mono-exponential decrease
described by 0.048∗ exp(−0.023∗t). This latter part corresponds to a
half-life of 30min.
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Fig. 3. (a) Illustration of a simulated arterial curve (full line) and its convolution (dotted
line) with a function g(t) from Eq. (3) with E= 0.85 and a = 0.25. (b) The arterial curve of
(a) has then been restored by convolution of the venous curve (full line) using the “inverse”
of the function g(t). The recalculated arterial curve agrees with the original within less than
1%. Inserts show the respective impulse response functions.
Convolution to Obtain Brain PK
The impulse responses as obtained above from PET data were in
turn used for each individual to obtain the time course of cold zolmitrip-
tan in brain by convolving plasma PK data with these impulse responses.
The results show that brain zolmitriptan increases with time, reaching
0.5mg/ml after about 0.5 hr and coming close to a maximum of 1.5mg/ml
after 2 hrs (Fig. 6).
Data Variability
The data obtained in this study are based on a rather small group of
individuals, but still allow for estimates on variability in the PK parameters.
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Fig. 4. Brain kinetic data (PET1, full line), averaged over all individual baseline studies.
Reconv1 (large filled circles) represents data obtained by convolving plasma with an impulse
response for plasma to brain transfer. This impulse response is described as a three-exponential
with parameters obtained by fitting Eq. (1) to actual data. The deviation in AUC compared
to the original brain data is 10%. Reconv2 (smaller circles) represents data obtained where the
impulse response from plasma to brain, is described by a three-exponential combined with a
three point description of the “inverse” of arterial-to-plasma impulse response. Then plasma
was convolved with the combination of these two impulse responses. The deviation in area
from the original brain data is 2.2%. (b) represents a magnification of (a) and shows that the
inclusion of an additional arterial-to-venous convolution term improves the description.
The differences in values between baseline and after drug administration
were determined. The ratio of the integral of the impulse response com-
paring post nasal spray to baseline study was on the average 1.11 with a
CV of 14%, suggesting lack of difference between the two instances and an
inter-occasion variability of the order of 14%. The integral of the impulse
response at baseline was on the average 0.24 with a 14% CV when compar-
ing the different individuals, suggesting that the inter-individual differences
in brain penetration were smaller than or of the same order as the method
variability. The AUC of the plasma radioactivity in the baseline studies was
on average 60 SUV∗min with a CV of 25%. The AUC of plasma PK was on
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Fig. 5. Impulse responses determined with two concepts: Imp1 from a three-exponential fit,
Imp2 from three-exponential combined with an arterial-to-venous “inverse” impulse response.
in (a) logarithmic scale and (b) in linear scale.
average 669 ng/ml∗min with a CV of 56%. However, one individual might
be an outlier with low PK-values (7 ng∗min) possibly related to an unfa-
vourable nasal absorption. Excluding this individual the average increased
to 768 ng/ml∗min and the CV decreased to 38%. The AUC of brain kinetics
of zolmitriptan showed an inter-individual variability of 42%.
Discussion
The present work presents a method whereby the brain kinetics of
a drug is described as a convolution of venous plasma kinetics with an
impulse response for exchange over the BBB. This impulse response is
derived from a PET study where the labelled drug is given as a short i.v.
infusion and plasma radioactivity is measured in venous blood samples
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Fig. 6. Plasma PK of zolmitriptan (upper line) after intranasal administration and brain
PK of zolmitriptan (lower line with diamonds) as obtained by convolution of plasma PK
with the impulse response for transfer from plasma to brain obtained from the PET study.
Method applied individually whereupon average determined over the group.
and brain radioactivity is measured with a PET camera. With the assump-
tion that this impulse response is unchanged in relation to the adminis-
tration route and the actual plasma kinetics, the brain kinetics from any
administration route can be derived as the convolution of the actual PK
with the impulse response.
In order to ensure one important condition for this concept, that
the exchange over the BBB is concentration independent, the study was
performed both at tracer concentration, that is before administration of
therapeutic amounts, and at a time point after administration of drug,
when close to maximum plasma concentration has been reached. The
data in the present study do suggest that the exchange of zolmitriptan
over the BBB is independent of drug concentration in plasma, since the
impulse responses obtained at the two occasions were not statistically sig-
nificantly different. The ratio of the integral of the impulse response after
and before drug administration was 1.11 (SD: 0.16) and the shapes of
the impulse responses were the same. The proposed methodology might
give the opportunity to correct for non-linearities by including an impulse
response function which change with plasma concentration. In such case
the mathematical operation would not be denoted convolution but rather
integral transformation. However, such operation would only be adequate
if the full concentration dependence was known and considered. Biological
factors which could give rise to lack of dose-linearity and time indepen-
dence, and hence invalidate the suggested method, include: saturable trans-
port and efflux over the BBB because of selective pump systems, saturable
enzymes in the BBB, physiological effects on the capillaries by the drug,
e.g. exerting effects on cerebral blood flow.
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A more direct way of performing a pharmacokinetic study with PET
is to have the tracer and drug mixed and co-administered. This mode is
ideal for i.v. administrations and will then give the possibility to directly
derive organ kinetics. The drug concentration is simply achieved by multi-
plication of the tracer SUV with administered drug in mg/kg. This concept
is, however, not always possible to utilize. One situation could be when an
i.v. administration formulation is not available or more difficult to apply.
Another situation is when the preferred route of administration is other
than i.v. Finally, instances when the drug has a very slow kinetics com-
pared to the possible follow up time with PET could make it difficult to
use a co-injection scheme.
In the PET field, the exchange of tracers over the BBB has predomi-
nantly been described by compartment modelling (23,24), although a spec-
tral analysis method has been described by Cunningham and Jones (25).
Similarly to the method described in the present communication, such
concepts would allow a definition of exchange parameters, which through
mathematical modelling could be applied on plasma PK to derive organ
kinetics. We have, however, preferred to use the convolution concept since
it conceptually suggest an exchange process rather than dividing the phar-
macokinetic events into compartments, which can lead to oversimplifica-
tions in the descriptions of the biological complexity. However, the two
modes may mathematically be equivalent if the parameters in the convolu-
tion is limited. Both methods have in common that they may need addi-
tional parameters to include non-linearity with dose and with time. The
convolution concept is also used in other aspects of pharmacology, e.g.
IVIVC (26) and in certain in silico-in vivo predictions (27). A special fea-
ture has been introduced here, and that is the utilisation of venous blood
samples for description of plasma radioactivity kinetics. One motivation
for this is the fact that traditional PK is derived from venous plasma
samples and therefore a direct conversion from a PET tracer study to
PK data should also involve radioactivity derived from venous plasma
samples. Otherwise a separate determination of the venous-to-arterial con-
version must be made.
Some studies have demonstrated erroneous PK parameters when
based on venous concentrations (28). Hysterisis (i.e. a delay between brain
concentration and effect, which has been shown when predicting brain
concentration utilizing venous PK data) has been demonstrated to be an
artifact related to a delay between arterial and venous PK data (29,30).
Traditional PET modelling includes the acquisition of arterial blood
samples obtained with rapid sampling to supply the input function. In the
proposed scheme with implicit correction for the arterial-to-venous blood
impulse response, arterial sampling is avoided, which is of great advantage
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for the practical performance of the study. The method allows this func-
tion to be estimated, but it should not be taken in strict biological sense
as the arterial-to-venous conversion but only as part of a general impulse
response describing the relation between venous plasma and brain tissue.
The practical advantages of the proposed method includes the avoidance
of the ethical aspects of arterial sampling, with a slight risk for extensive
bleeding. Furthermore, there is a recommendation to limit arterial nee-
dles to maximum twice which may place limits in the planning of stud-
ies. The disadvantages could include that the true relation of venous to
arterial plasma curves are not known and when mathematically derived
could be slightly misleading. The method is less suited for a determina-
tion of a direct tissue influx parameter ki , but should adequately describe
the overall tissue PK of the drug. Further work with a direct measure-
ment of venous and arterial plasma kinetics of the tracer on an individ-
ual basis would allow a comparison between the true arterial-to-venous
impulse response and the mathematically derived.
The present study shows that zolmitriptan, with some caution with
respect to the inclusion of radiolabelled metabolites, does enter brain tis-
sue and that at a level which approaches 25% of the plasma concentra-
tion. The rate of passage over the BBB is rapid enough to give a brain
concentration of 0.5mg/ml at 30min after administration as a nasal spray.
Already 5min after nasal administration, a significant concentration of
zolmitriptan is detected in the brain. These data give new insights into the
brain distribution of zolmitriptan and can as such serve as a basis for the
speculation whether the effect is exerted inside the brain or is restricted to
effects on the brain capillary endothelium.
This study confirms that the major contribution to inter-individual
variability in organ kinetics of a drug is related to variability in plasma
kinetics which is in turn due to absorption, elimination and metabo-
lism. The kinetic parameters describing exchange over the BBB shows
a moderate variability between occasions in the same individual, of the
order of 14%. This is a combination of the precision of the different
measurements, including camera and plasma measurements, and individ-
ual physiological factors of the volunteer. Test–retest variability of other
types of PET studies has been shown to be of the order of 5–15% depend-
ing on tracer and analysis method (31–33). The inter-individual variability
of the impulse response describing passage over blood-brain-barrier was of
the order of 14%, which would also include the method variability, indi-
cating that in this volunteer material the BBB properties with respect to
zolmitriptan are very similar.
The AUC of the plasma kinetics of the tracer showed a CV of about
25%, indicating the further introduction of inter-individual variability by
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elimination and metabolism of the tracer. The highest variability of 38%
was seen in the AUC of zolmitriptan plasma concentrations. This includes
the different factors of elimination and metabolism but suggests that a
dominant source of variability of drug kinetics in this case is the degree
of absorption of zolmitriptan over the nasal mucosa. Combining this with
the variability of the passage over the BBB, the brain concentration of
zolmitriptan showed an inter-individual variability of 42%.
CONCLUSIONS
This work illustrates a situation in which a PET study with i.v.
administration of the labelled drug [11C]-zolmitriptan has been used to
describe the exchange of drug between plasma and brain. This informa-
tion has in turn been applied on “cold” plasma concentration after a
therapeutic administration via nasal inhalation to describe the brain con-
centration kinetics of drug. The method utilizes a convolution modelling
in which plasma kinetics from venous blood sampling is used as input,
which simplifies the study as compared to most PET-modelling concepts
which require arterial blood sampling.
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